The prevalence of inflammatory bowel disease (IBD) among adults seems to be increasing significantly, yet there are signs that the utilization of biologics to treat patients with this chronic disease have plateaued.
The prevalence of inflammatory bowel disease (IBD) among adults seems to be increasing significantly, yet there are signs that the utilization of biologics to treat patients with this chronic disease have plateaued.
In the October 28, 2016 issue of Mortality Morbidity Weekly Review, researchers from the Centers for Disease Control and Prevention (CDC) announced the findings of its 2015 National Health Interview Survey on IBD. They estimated that the prevalence of IBD in the US adult population was 3.1 million (1.3% of the total US adult population). A similar study conducted in 1999 found the figure to be 1.8 million (or 0.9% of the adult US population), a 72% increase in number and a 44% increase by proportion of the population. According to the CDC, a dominating factor in this trend is a substantially higher prevalence of IBD identified among adults aged ≥45 years, mostly in Hispanics and non-Hispanic whites, and those in lower socioeconomic levels. The NHIS is based on the survey responses of more than 33,500 American adults.
This raises the question of whether the utilization of biologics used to treat IBD has also increased over this time. Remicade® was approved for use in 1998, and Humira® was approved in 2002 (the anti-TNF fusion protein etanercept was also approved in 1998, but is not indicated for IBD). These remain the two most commonly used agents to treat IBD, especially Crohn’s disease, with Cimzia® a distant third. Based on a single-center study from Stanford University, the utilization of biologics for adults and children with IBD has not increased proportionately. Use of Remicade® peaked in 2008, and utilization of Humira continued somewhat slow growth through 2012, the end of the data collection period. Interestingly, biologic use in IBD resulted in dramatic lowering of hospitalization costs, but not in the rate of abdominal surgery in these patients. They attribute this finding to the possible erosion of drug efficacy when given chronically over the long term. However, the Stanford researchers also found that pharmaceutical therapy in IBD, particularly Crohn’s disease, is the primary cost component in health care expenditures. “Pharmacy utilization costs account for nearly one-half (45.5%) of the total CD-attributable costs, exceeding inpatient care costs. Anti-TNF agents alone comprised nearly one-third (29.5%) of total costs,” they said.
The question of whether the biologic utilization pie is growing, shrinking, or remaining the same could have implications for the brand new biosimilar market for IBD.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.